Compare LyondellBasell Industries NV (LYB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Viatris Inc — how do they compare? LyondellBasell Industries NV trades at $63 (market cap $20.67B), while Viatris Inc trades at $16.26 (market cap $18.69B). The key difference: LyondellBasell Industries NV and Viatris Inc are close in size by market cap, and LyondellBasell Industries NV pays the higher dividend (6.44%). Which is the better fit depends on your goals.
| LYB | VTRS | |
|---|---|---|
Market Cap | $20.67B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $17.86 |
52-Week Low | $42.28 | $9.49 |
Enterprise Value | $32.26B | $30.80B |
Dividend Yield | 6.44% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $62.97, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $70.56. Recent Q2 2026 earnings of $4.30 per share beat estimates, driven by improved margins from supply disruptions and cost cuts. However, 2025 fundamentals show declining revenue to $30.15B and a net loss of $745M, though cash flow remains positive. The stock is near its 52-week high of $83.94, reflecting optimism around operational improvements.
Outlook: Near-term upside exists from earnings momentum and favorable supply dynamics, but risks include volatile chemical margins and high debt. Analyst sentiment is mixed with 46% buy ratings, suggesting cautious optimism amid cyclical challenges.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
